Thomas Marron, PhD, MD, discusses the end points of an exploratory study which examines the use of cemiplimab in hepatocellular carcinoma.
Thomas Marron, MD
Advertisement
Articles by Thomas Marron, MD
Thomas Marron, MD, discusses the rationale for investigating immunotherapy discontinuation in patients with melanoma.
Advertisement
Latest Updated Articles
Study of Cemiplimab Use in Hepatocellular Carcinoma Meets Primary End PointsPublished: February 26th 2022 | Updated:
Timing of Immunotherapy Discontinuation Remains Challenging in MelanomaPublished: November 20th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
